Pharmaceutical services company, Open Orphan has signed a new contract, valued at €4.4m, with a global pharmaceutical company to provide a respiratory syncytial virus (RSV) human challenge study trial.
The Dublin-listed company specialises in the testing of vaccines and antivirals through the use of human challenge clinical trials.
This study will take place in Open Orphan’s subsidiary hVIVO’s London-based quarantine unit, and is expected to be completed by the end of quarter one 2021.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).